BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22947059)

  • 1. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver.
    Abu-Elmagd KM; Wu G; Costa G; Lunz J; Martin L; Koritsky DA; Murase N; Irish W; Zeevi A
    Am J Transplant; 2012 Nov; 12(11):3047-60. PubMed ID: 22947059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
    Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
    Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.
    Kaneku H; O'Leary JG; Banuelos N; Jennings LW; Susskind BM; Klintmalm GB; Terasaki PI
    Am J Transplant; 2013 Jun; 13(6):1541-8. PubMed ID: 23721554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-specific antibody management in intestine transplantation: hope for improving the long-term durability of the intestine allograft?
    Hawksworth JS; Matsumoto CS
    Curr Opin Organ Transplant; 2019 Apr; 24(2):212-218. PubMed ID: 30694995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Including the liver in the visceral allograft: Impact on donor-specific anti-HLA antibodies and long-term outcomes.
    Abele D; Gäbel M; Oltean M; Varkey J; Mölne J; Ekwall N; Borg H; Jacobsson H; Holgersson J; Herlenius G
    Hum Immunol; 2024 Mar; 85(2):110767. PubMed ID: 38418315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients.
    Levitsky J; Kaneku H; Jie C; Walsh RC; Abecassis M; Tambur AR
    Am J Transplant; 2016 Aug; 16(8):2437-44. PubMed ID: 26896194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-Specific Antibodies in Pediatric Intestinal and Multivisceral Transplantation: The Role of Liver and Human Leukocyte Antigen Mismatching.
    Talayero P; Ramos Boluda E; Gómez Massa E; Castro Panete MJ; Prieto Bozano G; Hernández Oliveros F; López Santamaría M; Calvo Pulido J; Paz-Artal E; Mancebo E
    Liver Transpl; 2018 Dec; 24(12):1726-1735. PubMed ID: 30112820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited impact of pre-existing donor specific HLA-antibodies (DSA) on long term allograft survival after first adult liver transplantation.
    Koch M; Marget M; Sterneck M; Fischer L; Thude H; Nashan B
    Hum Immunol; 2018 Jul; 79(7):545-549. PubMed ID: 29669260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of preformed donor-specific antibodies and C4d on early liver allograft function.
    Perera MT; Silva MA; Murphy N; Briggs D; Mirza DF; Neil DA
    Scand J Gastroenterol; 2013 Dec; 48(12):1444-51. PubMed ID: 24131305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.